Adarza raises $25 million, moves toward commercialization
Adarza, based in Maryland Heights, makes diagnostic systems for researchers and drug companies. It plans to launch its testing platform commercially in June.
5
02, 2020
4
02, 2020
Adarza BioSystems Raises $25 Million in Series D Funding to Launch Platform for Research and Drug Development
Biotech company Adarza BioSystems announced today that it has raised $25 million in a Series D round co-led by 3x5 Partners, based in Portland, Ore., and St. Louis-based Lightchain Capital, LLC, the family office of Scottrade founder Rodger Riney. Adarza plans to use the funds to support full commercialization of ZIVA, its automated biological testing platform for academic and clinical research. Scheduled for commercial launch in June, the ZIVA platform will allow researchers to quickly identify inflammation, cardiovascular, and oncology protein biomarkers for disease profiling and drug development.
1
05, 2019
Adarza BioSystems to reveal ZIVA platform at AAI 2019
Adarza Biosystems, Inc. announced today that it will reveal its new protein multiplex instrument ZIVA at Immunology 2019, the annual meeting of the American Association of Immunologists (AAI) from May 9 - 13. Using a simple, time-saving workflow, the new automated system can simultaneously measure, analyze and report on up to 200 biomarkers.
11
06, 2018
Home Sweet Home: Adarza Settles into New Facility
Agreement gives Horizon exclusive right to supply services on Ardaza’s multiplex label-free immunoassay technology.
23
05, 2018
Adarza Sets Stage for Commercialization
Adarza Biosystems, Inc., a biotechnology company developing a novel protein and biomolecule detection platform, announced today that it has put in place the leadership, new manufacturing center and branding to begin selling its technology to researchers in the second quarter of 2019.